Dastgheib v. Genentech, Inc.

438 F. Supp. 2d 546, 2006 U.S. Dist. LEXIS 46901, 2006 WL 1892724
District Court, E.D. Pennsylvania·Decided July 10, 2006·No. Civil Action 04-1283·Published·Cited by 1 cases

Opinion

MEMORANDUM

EDUARDO C. ROBRENO, District Judge.

Before the Court is defendant’s motion in hmine to exclude the expert testimony of plaintiffs proposed expert economist, Joseph Gemini. For the reasons that follow, defendant’s motion will be granted in part and denied in part.

I. BACKGROUND

Mr. Gemini’s opinions can be summarized as follows:

1. “Since Dr. Dastgheib’s submissions (which Genentech is alleged to have wrongfully obtained) were critical in Genentech’s project to develop an anti-VEGF drug for the treatment of AMD, it is my opinion that the PTS adjusted NPV of Lucentis [ ($3.10 billion) ] can presently be deemed wrongfully obtained benefit subject to disgorgement as unjust enrichment damages.” (Supp.Exp. Rep.29.)
2. “In my opinion, at a minimum, the benefit of a shortened life of the AMD project would increase the value of this AMD project resulting from the ability to move forward more quickly.... Estimates indicated that a shift out of the launch date could cost [$332 million] in value for 1 quarter and [$628.6 million] for two quarters.... ” (Exp. Rep. ¶¶ 43-44; Sec. Supp. Exp. Rep. ¶ 32.)
3. “Assuming liability under [the North Carolina unfair and deceptive trade practices claim], and assuming that Dr. Dastgheib is entitled to immediate payment of the full value of the contract based upon future revenues, it is my opinion that the total present value ... of this expected royalty stream discounted to today is ... $55.63 million adjusted for [probability of technical success],” or $166.89 million if treble damages is awarded. (See.Supp.Exp.Rep.lffl 38-39.)
4. “I understand that the damages for fraud would be measured by the difference between what was received by Dr. Dastgheib, which was nothing, and what Genentech promised him, which was 1% of the Lucentis revenues.... Assuming liability under the fraud claim, and assuming the Dr. Dastgheib is entitled to immediate payment of the full value of what Genentech promised him based on future revenues, it is my opinion *548 that the total present value of this expected royalty stream discounted to today is ... $55.63 million adjusted for [probability of technical success],” plus punitive damages. (Sec. Supp.Exp.RepJ 41.)

Defendant contends that Mr. Gemini’s opinions, with respect to damages for (A) unjust enrichment, and (B) the North Carolina unfair trade practices and fraud claims, are inadmissible under Rule 702. 1

II. DISCUSSION

A. Unjust Enrichment

Defendant argues that Mr. Gemini’s opinion that plaintiff is entitled to the entire value of the Lucentis project as a damages remedy for unjust enrichment should be precluded under the reliability requirement of Rule 702. Defendant believes that Mr. Gemini erred in that he “has not even attempted to quantify the value of the Dastgheib materials, separated and apportioned from the contributions that others made to the project.” (Def.’s Br. 6.) Defendant contends that as a matter of North Carolina law, plaintiff is not entitled to the value of the entire Lucentis project even if Mr. Gemini is to assume that plaintiffs contributions were “necessary” for the development of Lucentis.

Defendant directs the Court to a litany of cases, only two of which could potentially assist the Court in predicting how the North Carolina Supreme Court would decide the apportionment issue with respect to unjust enrichment damages: (1) Metric Constructors, Inc. v. Bank of Tokyo-Mitsubishi, Ltd., 72 Fed. Appx. 916 (4th Cir.2003) (unpublished), and (2) Fed. Deposit Ins. Corp. v. British-Am. Corp., 755 F.Supp. 1314 (E.D.N.C.1991). 2 See, e.g., Debiec v. Cabot Corp., 352 F.3d 117, 128 (3d Cir.2003) (the role of a court sitting in diversity is to predict how the supreme court of the relevant state would decide the case).

Defendant heavily relies on the Fourth Circuit case of Metric, 72 Fed.Appx. 916. In Metric, plaintiff construction company contracted with Carolina Energy, Limited Partnership (“CELP”) to build a facility that would convert solid waste into fuel and recyclable materials. Id. at 918. CELP entered into a separate project financing agreement with a bank, the defendant in the case. Id.

Under the construction contract between CELP and plaintiff, CELP would make “progress payments” to plaintiff. Id. Having few assets of its own, CELP never paid plaintiff directly. Id. Instead, CELP submitted an application to the bank for release of funds to pay plaintiff. Id.

There were no problems for the first nine months of construction, at which time *549 the bank became concerned about the continued financial viability of the project. Id. at 919. The bank made the October payment to plaintiff for the previous month’s work, but did not make the November payment for October’s work. Id. However, neither CELP nor the bank alerted plaintiff of the pending financial concerns. Id. Plaintiff thus continued construction until mid-December, at which time CELP notified plaintiff that defendant bank had ceased funding on the project. Id. at 919-20. Plaintiff stopped work for non-payment and brought an unjust enrichment suit against the bank (not CELP), seeking the value of the benefit conferred on the bank for plaintiffs uncompensated work from October until mid-December. Id. at 920.

Before the Fourth Circuit was the appropriateness of plaintiffs claim for unjust enrichment under North Carolina law. With respect to damages, the court held,

The restitution to be made for unjust enrichment is measured according to the value of the benefit conferred on the defendant, not the plaintiffs loss. Booe, 369 S.E.2d at 556. In this ease, the value of the benefit conferred on the Banks should be measured as the amount by which [plaintiffs] additional work from October through mid-December enhanced the value of the Bank’s collateral. See Britt, 359 S.E.2d at 470.

Metric, 72 Fed.Appx. at 923.

Free access — add to your briefcase to read the full text and ask questions with AI

Dastgheib v. Genentech, Inc., 438 F. Supp. 2d 546, 2006 U.S. Dist. LEXIS 46901, 2006 WL 1892724 (E.D. Pa. 2006).

438 F. Supp. 2d 546 (Dastgheib v. Genentech, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Dastgheib v. Genentech, Inc.
457 F. Supp. 2d 536 (E.D. Pennsylvania, 2006)